Squarepoint
DNA icon

Squarepoint’s Ginkgo Bioworks DNA Stock Holding History

Squarepoint’s Portfolio DNA Stock Details DNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-2,013
Closed -$93.4K – 4182
2024
Q1 		$93.4K Buy
+2,013
New +$104K ﹤0.01% 3809

Other funds holding DNA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ACG
Anchorage Capital Group New York $450M AUM 41.75% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JMFC
J.M. Forbes & Co Boston, Massachusetts $1.27B AUM 26.46% 1-Year Est. Return

Squarepoint's DNA Position: Q2 2026 in Review

Squarepoint reduced its Ginkgo Bioworks (DNA) stake by 71% in Q2 2026, selling an estimated $328K and leaving 15,689 shares worth $155K. The position accounts for ﹤0.01% of the portfolio, ranked #4123.

Squarepoint first reported a position in DNA in Q1 2022 and has held it in 12 quarters since. The position peaked at $1.94M in Q1 2023. 184 funds tracked by Wall St. Rank hold DNA as of Q2 2026.

  • Squarepoint held 15,689 shares of Ginkgo Bioworks worth $155K as of Q2 2026.
  • Squarepoint sold 39,241 Ginkgo Bioworks shares in Q2 2026, an estimated $328K.
  • Ginkgo Bioworks made up ﹤0.01% of Squarepoint's portfolio in Q2 2026, its #4123 holding.
  • Squarepoint first reported a position in Ginkgo Bioworks in Q1 2022 and has held it in 12 quarters since.
  • Squarepoint's Ginkgo Bioworks position peaked at $1.94M in Q1 2023.
  • 184 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q2 2026.

Based on Squarepoint's 13F filing for Q2 2026, filed 14 Aug 2026.